IND accepted by the FDA
On Feb. 4th, Cellestia received the green light from the FDA for its Investigational New Drug Application (IND). The FDA completed its review, and concluded that Cellestia can proceed with its clinical investigation of CB-103 in tumors driven by an oncogenic NOTCH signaling pathway.
Cellestia Biotech AG secures CHF 20 million in Series A funding
Cellestia announced today the close of a CHF 20 million Series A financing round. The financing will accelerate Cellestia’s ongoing clinical program, and advance its innovative R&D pipeline.
To read Cellestia’s press release click here.
Cellestia Winner of Venture Leaders China 2018
Cellestia selected as one of the 10 high growth Swiss start-ups composing the new Swiss National Startup Team. The team will fly to China for an exclusive 10-day roadshow for business and investor meetings in September organised by Venture Leaders / swissnex China, including the World Economic Forum Annual Meeting of New Champions in Tianjin
Cancer Care 2018
Oral presentation on CB-103 by Dr. Dirk Weber, Chief Medical Officer, at the “Cancer Care 2018 Innovation & Progress in Switzerland” meeting (Bern, September 14).
Gordon Research Conference
Oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the “Notch, Cancer and Therapeutics” session of the Gordon Research Conference on Notch Signaling in Development, Regeneration and Disease (Lewiston, July 22–27).
European Congress on Biotechnology
Dr. Raj Lehal, Chief Scientific Officer, has given an oral presentation at the European Congress on Biotechnology (Geneva, July 1–4).
8th Conference on NOTCH Targeting in Cancer
Meet the Cellestia team at the 8th Conference on NOTCH Targeting in Cancer (Cyprus, June 20–22).
Clinical Advisory Board
Cellestia strengthens its Clinical Advisory Board by appointing Dr. Carlos L. Arteaga as new member.
Dr. Arteaga is Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center, Dallas, Texas. Dr. Arteaga is a world-renown leading figure in the field of breast cancer translational medicine and clinical research, serving in the advisory boards of several academic Breast Cancer Programs and NCI-designated Cancer Centers.
Clinical Advisory Board
Cellestia appoints Dr. Renata Ferrarotto as member of the Clinical Advisory Board.
Dr. Renata Ferrarotto is an Assistant Professor and the Director of the Head and Neck Clinical Research Program at MD Anderson Cancer Center, Houston, Texas. Dr. Ferrarotto is a scientific and clinical expert for head and neck malignancies and her work focuses on the clinical development of novel diagnostic and therapeutic strategies for salivary gland tumors, in particular for adenoid cystic carcinomas.
Strategic Advisory Board
Cellestia appoints David Epstein as Chairman of the Strategic Advisory Board.